naabt masthead for buprenorphine site

The National Alliance of Advocates
for Buprenorphine Treatment

Buprenorphine (Suboxone®, Subutex®3, Zubsolv®4, Bunavail™5, Probuphine®6) is an opioid medication used to treat opioid addiction in the privacy of a physician's office.1 Buprenorphine can be dispensed for take-home use, by prescription.1 This, in addition to the pharmacological and safety profile of buprenorphine, makes it an attractive treatment for patients addicted to opioids.2

Patient/Physician Discussion Guides

In 2014, the National Alliance of Advocates for Buprenorphine Treatment (NAABT) solicited response to an online survey to assess the challenges of opioid addiction treatment; 606 people with opioid addiction responded. Survey results indicate that many patients face challenges and difficulties that negatively impact their addiction treatment. A dialogue between the patient and physician is important to determine which of the various treatment plans may be appropriate. These Patient and Physician Discussion Guides are based on the NAABT survey results and can be used to help start this important conversation.*

The medical information in these guides is provided as an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. This information is not intended to be patient education, and should not be used as a substitute for professional diagnosis or treatment by a licensed healthcare provider.


*Both guides were created with the cooperation of a medical communications firm and supported by a grant from BioDelivery Sciences International, Inc. Other materials authored by NAABT,Inc. can be assumed to have no similar associations unless specifically noted.

This page was last modified on : 11/18/2014

The Purpose of Buprenorphine Treatment:

To suppress the debilitating symptoms of cravings and withdrawal, enabling the patient to engage in therapy, counseling and support, so they can implement positive long-term changes in their lives which develops into the new healthy patterns of behavior necessary to achieve sustained addiction remission. - explain -

The National Alliance of Advocates for Buprenorphine Treatment is a non-profit organization charged with the mission to:

  1. U.S. Food and Drug Administration, FDA Talk Paper, T0238, October 8, 2002, Subutex and Suboxone approved to treat opiate dependence.
  2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, Md: Substance Abuse and Mental Health Services Administration, 2004.
  3. Subutex Discontinued in the US market in late 2011.
  4. Zubsolv (bup/nx sublingual tablet) FDA approved 7/3/2013 see buprenorphine pipeline graphic -in pharmacies now.
  5. Bunavail (bup/nx bucal film) FDA approved 6/6/2014 see buprenorphine pipeline graphic -in pharmacies now.
  6. Probuphine FDA approved 5/26/2016 - FDA Probuphine press release